Risk Factors for Mortality in Patients with Anti-NMDA Receptor Encephalitis
Overview
Affiliations
Objective: Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a severe autoimmune disorder with a mortality of 5%-7%, but few studies have focused on the predictors of death in this disease. In this study, we aim to investigate predictors and causes of death in patients with anti-NMDAR encephalitis.
Methods: In this cohort study, patients with anti-NMDAR encephalitis were enrolled at the West China Hospital of Sichuan University between June 2011 and October 2015. The outcomes of patients were evaluated by long-term follow-up. Cox regression analysis was used to assess the association between potential predictors and death.
Results: Altogether 96 patients were included in this study, and 11 died after median 24.5 (7-57) months of follow-up. The mortality of anti-NMDAR encephalitis was 11.46%. Multivariate analysis results showed that Glasgow Coma Scale (GCS) score ≤8 at admission (HR=15.917, 95% CI=1.729-146.562; P=.015), the number of complications (HR=7.772, 95% CI=1.944-31.072; P=.004), and admission to an intensive care unit (HR=70.158, 95% CI=2.395-2055.459; P=.014) were significantly associated with increased risk of mortality. Twelve patients received second-line immunotherapy, and the cohort was relatively under-treated compared with other studies. The main causes of death were severe pneumonia, multiple organ dysfunction syndrome, and refractory status epilepticus.
Conclusion: GCS score ≤8 at admission, number of complications, and admission to an intensive care unit are predictors of death. Management of complications may improve the prognosis of anti-NMDAR encephalitis.
Brewinska L, Banasik A, Czopowicz M, Plonek M, Giza E, Czerwik A BMC Vet Res. 2025; 21(1):112.
PMID: 40011993 PMC: 11863485. DOI: 10.1186/s12917-025-04594-2.
Shan D, Zhang H, Cui L, Chai S, Chen W, Liu G Immun Inflamm Dis. 2024; 12(9):e70019.
PMID: 39315845 PMC: 11421047. DOI: 10.1002/iid3.70019.
Nair S, Koshy E, Kandikonda R, Kannoth S Neurodegener Dis Manag. 2024; 14(3-4):63-67.
PMID: 39155818 PMC: 11457615. DOI: 10.1080/17582024.2024.2388508.
Zhang J, Li Y, Liu L, Dai F, Peng Y, Ma Q BMC Neurol. 2024; 24(1):276.
PMID: 39123191 PMC: 11313159. DOI: 10.1186/s12883-024-03724-x.
Dai Y, Zhu Z, Tang Y, Xiao L, Liu X, Zhang M CNS Neurosci Ther. 2024; 30(7):e14821.
PMID: 38948940 PMC: 11215490. DOI: 10.1111/cns.14821.